Cardiac GSI Feasibility Study

NCT ID: NCT01816750

Last Updated: 2016-10-24

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

60 participants

Study Classification

INTERVENTIONAL

Study Start Date

2013-04-30

Study Completion Date

2016-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The recently introduced Computed tomography (CT) scanner, Discovery CT750 HD (GE Healthcare, Milwaukee), incorporates a battery of innovations aimed at improving diagnostic image quality, evaluating perfusion and assessing for scar, in an effort to address the current shortcomings of Computed tomographic coronary angiography (CTCA) in patients with significant coronary artery disease. The new scanner will use a novel method of scanning (Cardiac Gemstone Spectral Imaging - Cardiac GSI) and image reconstruction (Adaptive Statistical Iterative Reconstruction- ASIR) as opposed to standard definition 64-slice CT Multi-detector row computed tomography(MDCT)and Filtered Back Projection (FBP) used by the conventional CT scanners. The Cardiac GSI protocol enables the scanner to acquire images at two different x-ray energies almost simultaneously, which can be post-processed to selectively reduce beam hardening artefacts and delete materials with specific attenuating properties from the images, such as coronary calcium. ASIR offsets the potential increase in radiation dose required for Cardiac GSI scanning. This will potentially result in images of higher diagnostic quality with an equivalent or perhaps lower dose of radiation compared to present technology.

Furthermore, it is hypothesised that dual-energy acquisition may improve the accuracy of the assessment of perfusion.

Although initial in-vitro results are encouraging, this technology has not been rigorously assessed with regards to its feasibility and diagnostic quality, limiting its applicability in routine clinical practice. This assessment will require a trial comparing the accuracy of Cardiac GSI CTCA with that of Invasive coronary angiography (ICA) for anatomical assessment of stenosis, Myocardial Perfusion Imaging with Single Photon Emission Computed Tomography (MPI-SPECT) for assessment of perfusion and Cardiac Magnetic Resonance (CMR) for assessment of myocardial scar. We have designed a pilot study in this regard which will help us assess the feasibility of the scan protocol and provide data to power a larger study to assess the diagnostic remit of Cardiac GSI scanning in the assessment of patients with high-risk of significant coronary artery disease and myocardial scar.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

High Risk of Significant Coronary Artery Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

SINGLE

Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Anatomical accuracy Cardiac GSI vs ICA

The identification and quantification of coronary artery stenoses using Cardiac in comparison to ICA.

Group Type EXPERIMENTAL

Cardiac GSI

Intervention Type DEVICE

A novel method of computed tomography scanning (Cardiac Gemstone Spectral Imaging - Cardiac GSI) and image reconstruction (Adaptive Statistical Iterative Reconstruction- ASIR.

Stress perfusion Cardiac GSI vs MPI-SPECT

Assessment of the functional impact of coronary stenoses using Cardiac GSI in comparison to MPI-SPECT

Group Type EXPERIMENTAL

Cardiac GSI

Intervention Type DEVICE

A novel method of computed tomography scanning (Cardiac Gemstone Spectral Imaging - Cardiac GSI) and image reconstruction (Adaptive Statistical Iterative Reconstruction- ASIR.

Delayed enhancement Cardiac GSI vs CMR

Assessment of abnormal myocardial tissue characteristics representing ischaemic or scarred tissue using Cardiac GSI in comparison to CMR.

Group Type EXPERIMENTAL

Cardiac GSI

Intervention Type DEVICE

A novel method of computed tomography scanning (Cardiac Gemstone Spectral Imaging - Cardiac GSI) and image reconstruction (Adaptive Statistical Iterative Reconstruction- ASIR.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Cardiac GSI

A novel method of computed tomography scanning (Cardiac Gemstone Spectral Imaging - Cardiac GSI) and image reconstruction (Adaptive Statistical Iterative Reconstruction- ASIR.

Intervention Type DEVICE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Cardiac Gemstone Spectral Imaging

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Accuracy arm

* Patients \>50 years of age
* Suspected or known coronary artery disease referred for ICA

Stress perfusion arm

* Patients \>50 years of age
* Suspected or established coronary artery disease referred for MPI-SPECT for assessment of inducible ischaemia

Delayed enhancement arm

* Patients \>50 years of age
* Referred for CMR for assessment of myocardial viability/scar

Exclusion Criteria

Accuracy arm

* Consent cannot be obtained
* Patient BMI \> 30 kg /m2
* NYHA class III or IV heart failure
* Chronic total occlusion of target epicardial coronary artery
* Urgent revascularisation required
* Allergy to iodinated contrast or previous contrast induced nephropathy
* Intolerance or contraindication to beta-blockers
* Uncontrolled heart rhythm disturbances
* 2nd or 3rd degree atrioventricular block
* Estimated glomerular filtration rate \<30ml/min within two weeks prior to procedure or chronic renal failure on dialysis
* Pregnancy

Stress perfusion arm

* As above, plus:
* Asthma (any) or intolerance to adenosine

Delayed enhancement arm

\- As for Accuracy arm
Minimum Eligible Age

50 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University Hospital Plymouth NHS Trust

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Ben Clayton, MBBS

Role: PRINCIPAL_INVESTIGATOR

Plymouth Hospitals NHS Trust (UK)

Gareth Morgan-Hughes, MBBS

Role: PRINCIPAL_INVESTIGATOR

Plymouth Hospitals NHS Trust (UK)

Franchesca Wotton, MBBS

Role: STUDY_DIRECTOR

Plymouth Hospitals NHS Trust (UK)

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Plymouth Hospitals NHS Trust

Plymouth, Devon, United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United Kingdom

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

13/SW/0065

Identifier Type: OTHER

Identifier Source: secondary_id

13/P/031

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

High-Resolution CT for Heart
NCT07169201 NOT_YET_RECRUITING